Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx

Executed on:Jan 9, 2025 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

​Institution: Mass General

Clinical investigator and attending physician at Massachusetts General Hospital Cancer Center.
Treats patients with plasma cell dyscrasias with a particular focus on multiple myeloma as well as Waldenstrom’s macroglobulinemia and other IgM-related disorders.
Research interests include global health, studying immune dysregulation, and developing more effective oncologic treatment strategies, which minimize toxicity and infectious complications.

Interview Goal

This interview aims to explore the recent advancements and clinical data presented by Legend Biotech and J&J regarding their CARVYKTI (ciltacabtagene autoleucel; cilta-cel) program for multiple myeloma. We will also discuss the potential of Anito-Cel, currently in development by Gilead/Acellx.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.